Breaking news on irritable bowel syndrome
(IBS)
Anti-depressants May Benefit Some Patients With Irritable Bowel Disease published
Tue, 06 May 2008 01:00:00 PDT
Theories abound about the cause of Irritable Bowel Disease (IBD): Diet? Stress? Perhaps an infection? On the other hand, is it possible depression could be triggering the disease in some of the 20 per cent of Canadians suffering from this digestive system disorder? New research conducted by scientists in McMaster University's Intestinal Disease Research Program suggests it's highly likely that in some patients depression is wreaking havoc on the gut.
Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents published
Fri, 02 May 2008 00:00:00 PDT
Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS.The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States.
Sucampo Pharmaceuticals Obtains FDA Approval For AMITIZA(R) For The Treatment Of Irritable Bowel Syndrome With Constipation In Adult Women published
Wed, 30 Apr 2008 16:00:00 PDT
Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S.
FDA Approves Amitiza For IBS-C - Only Drug Available In USA For Irritable Bowel Syndrome With Constipation published
Wed, 30 Apr 2008 03:00:00 PDT
The U.S. Food and Drug Administration approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over. There is currently no prescription drug therapy for IBS-C. With this approval, Amitiza becomes the only FDA-approved medical treatment for IBS-C available in the United States. Irritable bowel syndrome is a disorder characterized by cramping, abdominal pain, bloating, constipation, and diarrhea.
Callisto Pharmaceuticals Files IND For SP-304 (Guanilib) In Chronic Constipation And Irritable Bowel Syndrome published
Thu, 10 Apr 2008 01:00:00 PDT
Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. SP-304 is an analog of uroguanylin, a natural hormone produced in the gastro-intestinal (GI) tract that is a key regulator of intestinal function.
Food For Life Baking Co., Inc. Recalls Spelt Bread , California - Product Contains Undeclared Wheat published
Thu, 20 Mar 2008 01:00:00 PDT
Food For Life Baking Company of Corona, California is voluntarily recalling 2,241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat. People who have allergies to wheat or those with Celiac Disease may run the risk of a serious or life threatening allergic reaction if they consume spelt products. The recalled products were sold nationwide through health food distributors and natural food retailers.
Abuse History Affects Pain Regulation In Women With Irritable Bowel Syndrome published
Sat, 02 Feb 2008 00:00:00 PDT
UCLA and University of North Carolina researchers have found that women with irritable bowel syndrome (IBS) who have experienced sexual and/or physical abuse may have a heightened brain response to pain that makes them more sensitive to abdominal discomfort. IBS is a condition that affects 10 to 15 percent of the population and causes gastrointestinal discomfort along with diarrhea, constipation or both.
Allergic Disease Linked To Irritable Bowel Syndrome published
Thu, 24 Jan 2008 00:00:00 PDT
Adults with allergy symptoms report a high incidence of Irritable Bowel Syndrome (IBS), suggesting a link between atopic disorders and IBS according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).In a study of 125 adults, Mary C. Tobin, M.
Scientists Uncover New Potential Treatment For Inflammatory Bowel Disease published
Tue, 15 Jan 2008 00:00:00 PDT
Irish scientists have discovered a new potential therapeutic approach to Inflammatory Bowel Disease (IBD), a chronic debilitating disease involving inflammation of the intestine which affects more than 15,000 people in Ireland and millions of people worldwide. People suffering from IBD can experience an array of symptoms ranging from mild discomfort to debilitating disease requiring surgical removal of large parts of the intestine.
Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel Syndrome With Constipation published
Fri, 09 Nov 2007 13:00:00 PDT
Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c). This DDP733 Phase 2b trial is a randomized, double-blind, placebo controlled study that is enrolling female patients with IBS-c at multiple centers in the U.S. and Canada.
MayoClinic.com Focuses On Diagnosing Fibromyalgia Symptoms published
Thu, 08 Nov 2007 01:00:00 PDT
Fibromyalgia is a chronic condition characterized by widespread pain in your muscles, ligaments and tendons, as well as fatigue and multiple tender points. A new feature on mayoclinic.com provides users with information regarding the process for diagnosing fibromyalgia. Because there is no single, specific diagnostic laboratory test, diagnosis can be difficult.
Superior Remission Rates For Once Daily Use Of Pentasa(R) (mesalazine) In Ulcerative Colitis published
Wed, 31 Oct 2007 01:00:00 PDT
For the first time a once daily dosing regime of mesalazine (Pentasa(R) granules) has proven to be statistically superior to twice daily dosing for the effective maintenance of remission in patients suffering from mild to moderate ulcerative colitis (UC), finds a trial presented at the 15th United European Gastroenterology Week (UEGW) congress.
Impact On Productivity From Functional Gastrointestinal Disorders Measured By Study published
Tue, 16 Oct 2007 06:00:00 PDT
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.Functional gastrointestinal disorders are associated with impaired quality of life and are among the most common causes of work-related absenteeism.
Cancer Protection and Mesalamine Linked For High Risk Inflammatory Bowel Disease Patients published
Tue, 16 Oct 2007 06:00:00 PDT
Colorectal screening remains essential for those with IBDResearchers found that mesalamine use among patients with inflammatory bowel disease was associated with a decrease in incidence of colorectal cancer when comparing cases and controls.
Results Of Review Of Probiotic Research published
Tue, 16 Oct 2007 05:00:00 PDT
A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis®, Bifidobacterium infantis 35624, the sole ingredient in Align® (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study.
Review Of Probiotic Trial Research Finds Only Bifantis(R) Able To Claim Efficacy Versus Placebo For IBS Symptoms published
Tue, 16 Oct 2007 00:00:00 PDT
A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis(R), Bifidobacterium infantis 35624, the sole ingredient in Align(R) (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study.
FDA Accepts Sucampo's SNDA For Lubiprostone (8 Mcg) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) published
Tue, 18 Sep 2007 00:00:00 PDT
Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA). Sucampo Pharmaceuticals currently anticipates a decision from the FDA in the second quarter of 2008.
Lexicon Presents Class Of Compounds Modulating TPH1, The Target For Its LX1031 Investigational Drug For Irritable Bowel Syndrome published
Wed, 22 Aug 2007 00:00:00 PDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. LX1031 is currently under evaluation in a Phase 1b clinical trial in healthy volunteers.
Important Facts About Irritable Bowel Syndrome published
Thu, 09 Aug 2007 00:00:00 PDT
Irritable Bowel Syndrome (IBS) is a disorder of bowel function. Patients who suffer from irritable bowel syndrome have abdominal pain or discomfort accompanied by changes in bowel habits such as constipation or diarrhea (or both). Additional symptoms of IBS include abdominal bloating, loss of appetite, and general malaise.IBS is an extremely common disorder. Studies have estimated the prevalence in the United States to be somewhere between 15% and 20% of the entire population.
Management Of Inflammatory Bowel Disease Improved By Biologics published
Sun, 29 Jul 2007 09:00:00 PDT
The use of biologic agents for the treatment of inflammatory bowel disease (IBD) may benefit patients, but doctors need to consider the potential associated side effects in determining treatment course, according to a consensus paper published in this month's issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
Zelnorm(R) To Be Made Available To US Patients Under Restricted Access Program published
Sat, 28 Jul 2007 00:00:00 PDT
In cooperation with the US Food and Drug Administration (FDA), Novartis has established a restricted access program for Zelnorm(R) (tegaserod maleate) so that patients in need of this medicine can be considered for treatment.
Supplemental New Drug Application For Lubiprostone To Treat IBS With Constipation Submitted By Sucampo Pharmaceuticals published
Tue, 17 Jul 2007 03:00:00 PDT
Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).
Sucampo Pharmaceuticals Submits Supplemental New Drug Application For Lubiprostone To Treat Irritable Bowel Syndrome With Constipation published
Fri, 13 Jul 2007 00:00:00 PDT
Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).
Heart Drugs May Help People With Bowel Disorders published
Sat, 07 Jul 2007 01:00:00 PDT
Statin drugs which are widely prescribed to prevent heart disease may emerge as a future treatment for Crohn's disease, an inflammatory bowel condition, a scientist said last Tuesday. Surgical research fellow Dr. John Burke was addressing the Association of Coloproctology meeting in Glagow about research which is reinforcing the idea that statins are becoming 'the aspirin of the 21st Century'.
A Psychological Approach To The Management Of Irritable Bowel Syndrome published
Wed, 30 May 2007 07:00:00 PDT
Antidepressants and psychological treatments such as hypnotherapy have the potential to help patients with severe irritable bowel syndrome (IBS), say researchers in this week's BMJ.IBS is a very common disorder, but conventional 'physical' treatments often do not work very well and patients can feel that their symptoms are being ignored, downplayed or misunderstood.
)
|
|
